Print this page    •   Back to Web version of article

Medical News
Texas Biomed Files Patent Application for Novel HIV Vaccine

November 20, 2012

The Texas Biomedical Research Institute (Texas Biomed) has applied for a patent for a genetically-engineered vaccine for HIV prevention. The vaccine is designed to be administered in a single dose that will last the patient a lifetime. It targets the outer layers of the body structures that first come into contact with the virus. Officials at Texas Biomed believe that the vaccine could be adapted for use against other infections.

Marie-Claire Gauduin, Ph.D., of Texas Biomed's Department of Virology and Immunology is co-inventor on the patent with Philippe Blancou, Ph.D., a visiting scientist from the University of Nice-Sophia Antipolis in France. Gauduin stated that the development of an effective AIDS vaccine that restricts viral replication at the mucosal level of entry may be the best hope of controlling HIV. She added that only life-long stimulation of the immune system by the vaccine will be sufficient to achieve long-term protection.

Back to other news for November 2012

Excerpted from:
San Antonio Business Journal
11.19.2012; W. Scott Bailey




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/69806/texas-biomed-files-patent-application-for-novel-hi.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.